Efficacy and Safety Study of cediranib in combination with olaparib in Patients with Recurrent Platinum-Resistant Ovarian Cancer

Trial Identifier: D8488C00001
Sponsor: AstraZeneca
Collaborator:
Myriad Genetic Laboratories, Inc.
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc
NCTID:: NCT02889900
Start Date: January 2017
Primary Completion Date: August 2019
Study Completion Date: March 2021
Condition: Ovarian Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Translation
Spanish Translation

Trial Locations

Country Location
US, AK Anchorage, AK, US, 99508
US, AL Mobile, AL, US, 36604
US, CA Downey, CA, US, 90241
US, CA Greenbrae, CA, US, 94904
US, CA Orange, CA, US, 92868
US, CA San Diego, CA, US, 92123
US, CA West Hollywood, CA, US, 90048
US, FL Miami, FL, US, 33176
US, FL Miami, FL, US, 33136
US, FL Orlando, FL, US, 32804
US, GA Augusta, GA, US, 30901
US, GA Newnan, GA, US, 30265
US, IN Fort Wayne, IN, US, 46804
US, KS Westwood, KS, US, 66205
US, LA Covington, LA, US, 70433
US, MA Boston, MA, US, 02215
US, MD Towson, MD, US, 21204
US, MT Billings, MT, US, 59101
US, NC Charlotte, NC, US, 28204
US, NC Winston Salem, NC, US, 27103
US, NY New York, NY, US, 10032
US, NY Rochester, NY, US, 14642
US, TN Knoxville, TN, US, 37920
US, WA Seattle, WA, US, 98104